Ongoing anti-HT treatment in the HT group included angiotensin II receptor blockers (nine participants), β-blockers (three participants), ACE inhibitors (two participants), calcium antagonist (one participant), combinations of angiotensin II receptor blockers + calcium antagonist (two participants), and calcium antagonist + β-blocker (one participants). Here, ACE is linked to hematocrit.